Javier Pinilla-IbarzMei XueElizabeth WuKaitlyn EsselmanWesley FurnbackSwetha ChallagullaKeri Yang2026-03-222026-03-22202610.1080/17474086.2026.2628549https://doi.org/10.1080/17474086.2026.2628549https://andeanlibrary.org/handle/123456789/79633Zanubrutinib was associated with lower 90-day switching rates and estimated proportion of patients receiving next line of therapy at 180 days vs acalabrutinib and ibrutinib in 1L and 2L.enIbrutinibMedicineChronic lymphocytic leukemiaCancer researchBruton's tyrosine kinaseLymphomaOncologyInternal medicineAntibody therapyLeukemiaReal-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphomaarticle